Join to View Full Profile
825 Eastlake Ave ESeattle, WA 98109
Phone+1 206-520-5000
Dr. Fong is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Lawrence Fong, MD is an Oncologist based in Seattle, WA. He completed ellowship from Stanford and a residency from the University of Washington. He currently serves as a Professor at Fred Hutchinson Cancer Center. He boasts an experience in cancer immunotherapy, and has featured in numerous academic publications, specifically investigating immune checkpoint inhibitor and developing new therapeutics for cancer. Dr. Fong founded and led the Cancer Immunotherapy Program at UCSF that performs clinical trials with immunotherapy, prior to moving to the Fred Hutch Cancer Center to lead the Integrated Immunotherapy Research Center. He was recognized for his prowess in healthcare with the CMS Meaningful Use Stage 1 Certification from EpicCare Ambulatory EMR, Epic Systems Corporation in 2012-2013.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1994 - 1998
University of WashingtonResidency, Internal Medicine, 1991 - 1994
Stanford University School of MedicineClass of 1992
Certifications & Licensure
WA State Medical License 2024 - 2026
CA State Medical License 1994 - 2025
American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer Start of enrollment: 2006 Jul 01
- Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer Start of enrollment: 2011 May 23
- Ipilimumab and GMCSF Immunotherapy for Prostate Cancer Start of enrollment: 2015 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- Tumor cell heterogeneity drives spatial organization of the intratumoral immune response.Miho Tanaka, Lotus Lum, Kenneth H Hu, Piyush Chaudhary, Savannah Hughes
The Journal of Experimental Medicine. 2025-06-02 - Impact of tumor localization on antitumor immunity with conditionally activated CTLA-4 blockade.Marcel Arias-Badia, Chien-Chun Steven Pai, Yee May Lwin, PeiXi Chen, Aahir Srinath
Journal for Immunotherapy of Cancer. 2025-04-02 - Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostat...Rahul R Aggarwal, Jacqueline Vuky, David VanderWeele, Matthew Rettig, Elisabeth I Heath
Journal of Clinical Oncology. 2025-03-26
Press Mentions
Researchers Have Brought the Promise of Stem Cell Therapies Closer to RealityNovember 24th, 2024- Overcoming the Challenges of Applying CAR T-cell Therapy to Solid TumorsNovember 8th, 2024
- Leaving Lymph Nodes Intact Could Increase Efficacy of Cancer ImmunotherapyApril 12th, 2023
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
